The power of engineered T cells – a new treatment option for cancer patients ….and more !

The power of engineered T cells – a new treatment option for cancer patients….and more !

The use of T cell receptor-directed T cells to target cancer antigens is an exciting area of cancer research. Realising the full potential of a personalised therapy option, it still presents challenges.

There is a clear need for collaboration between researchers, clinicians and industry leaders to overcome these challenges and advance the field of T-cell receptor-directed therapy opportunity. The potential benefits of this approach are significant, and with continued research and development, there is potential for personalised and effective treatments.

CAR-T cell therapies are a promising new approach to cancer treatment that is gaining increasing attention around the world. In Germany, the introduction of CAR-T cell therapies has been relatively slow, but the country is starting to make up ground. 

For CAR-T cell therapies, the patient’s own T cells are genetically modified to recognise and target cancer cells. For this purpose, a chimeric antigen receptor (CAR) is added to the surface of the T cells, allowing them to recognise and bind to specific proteins on the surface of cancer cells. Once the CAR T cells have bound to the cancer cells, they can destroy them.

The first CAR-T cell therapy was approved by the FDA in the United States in 2017, and since then several more CAR-T cell therapies have been approved in the US and Europe. These treatments have shown remarkable results in clinical trials. By the end of 2021, three autologous anti-CD19 CAR-T cell products, Yescarta, Kymriah and Tecartus, received marketing approval based on positive clinical data from phase I/II trials. In the EU, all three products have been subject to an accelerated review (PRIME designation process) to facilitate the development and clinical use of advanced therapy medicinal products that meet an unmet medical need.

CAR-T cell therapies are not yet widely used in Germany, but the country is starting to catch up with other countries in terms of acceptability. Several clinical trials of CAR-T cell therapies are currently in progress in Germany, including trials for the treatment of lymphoma, leukaemia and multiple myeloma.

Challenges to introducing CAR-T cell therapies in Germany include the financial investment required for these treatments. The production and administration of CAR-T cell therapies are still quite cost-intensive, so health insurance companies are still hesitant to cover the costs of these treatments. However, as more data on the efficacy of these therapies becomes available, it is likely that more health insurance providers will cover the costs.

Despite the challenges, the potential benefits of CAR-T cell therapies are significant. CAR-T cell therapies are a highly personalised treatment that is tailored to each individual patient. This treatment offers versatile and personalised ways to treat different types of cancer. The potential for other personalised immunotherapies is also of great interest. For patients who have exhausted all other treatment options, CAR-T cell therapies offer hope.

CAR-T cell therapies are an exciting new development in cancer treatment and more. While the introduction of these therapies in Germany has been slow, the country is starting to make up ground with several clinical trials currently ongoing. As more and more data becomes available on the effectiveness of these treatments, it is likely that CAR-T cell therapies will become an important treatment option.

It remains exciting…

#clinicalresearch #outsource #clinicaltrials #consulting #research #researchanddevelopment #share #like #healthcare
#biotech #pharma #medicine #oncology #lifescience #neurology #autoimmune #immunology #clinicaldevelopment #clinicaltrial #ClinicalResearchOrganisation #celltherapy #cartcelltherapy #biotech #biotechnology #cancerresearch #cancer #immunology #immunooncology #immunotherapy #collaboration

The Future for Clinical Research and Development in Germany – What’s Next ?

The Future for Clinical Research and Development in Germany

What’s Next ? Reduce dependencies, take more risks!

Prof. Bernd Raffelhüschen is a famous German economist who has been drawing attention to the demographic changes in Germany for years.  
In his lectures he often suggests and calls for a more independent position from the demographic problems in Germany.

In the scope of many conferences and network cooperations, REAgency+ is a representative for the promotion of young academics and a contact person for business advice and development in clinical research. In the interaction with young research academics, innovators and industry, there is a great demand for business and personal development opportunities, added value in collaboration and an effective value chain.

Bernd Raffelhüschen, for example, once recommended in one of his lectures to focus on future-relevant areas and to push the development of new industries and technologies. Economic growth should be supported and the quality of life in Germany improved.

Providing research funding, especially for areas relevant to the future, can help researchers develop their skills and expertise.
Above all, and REAgency+ is committed to and supports this approach, it is particularly important to promote a culture of innovation. Raffelhüschen suggests to be encouraged to take risks and explore new ideas.

International collaboration also creates opportunities for researchers to work with international partners.
Business entrepreneurship needs to be boosted and researchers need to be supported more. Start-ups and small businesses could be supported more by a supportive legal environment.

What is your opinion on the topic?

Here is one of the available lectures by Prof. Bernd Raffelhüschen

#clinicalresearch #outsource #clinicaltrials #consulting #research #researchanddevelopment #healthcare
#biotech #pharma #medicine #oncology #lifescience #neurology #autoimmune #immunology #clinicaldevelopment #clinicaltrial #ClinicalResearchOrganisation  #regulatoryaffairs #demographics #futureofhealthcare # #entrepreneurship #work #innovation #opportunities #funding #growth #future #development #academics #researchers

Breaking Down the Expectation-Reality Gap in Outsourcing Solutions

Breaking Down the Expectation-Reality Gap in Outsourcing Solutions

Following numerous meetings held last week, the central theme of discussion was centered around CRO outsourcing solutions in the clinical research industry. Over the past few years, there has been a rising expectation which has often been met with certain limitations. If you have personally experienced any challenges while working with service providers, we welcome you to share your experiences with us.

Outsourcing services to CROs is very popular in clinical research. Increasingly, companies want to focus on their core competencies and/or separate from peripheral areas. In addition, outsourcing can reduce costs and increase efficiency. In this context, the success of outsourcing solutions depends on the right strategy. Currently, there is an increasing requirement for the know-how of consultants and experts to launch efficient outsourcing solutions. Benefit from a strong, efficient team! REAgency+ promotes added value for employees and growing company structures for success. The introduction of functional areas should not only demonstrate business growth, but also a strategic vision and action plan. REAgency+ has the vision to create added value in the collaboration with growing, researching corporate structures. Our focus is on sustainable collaboration and access to effective expert solutions for growing, research-based companies. Flexible, with the ability to define, adapt and integrate new work processes. From experience REAgency+ knows that to achieve impact, expertise for clinical operational projects must be defined and implemented in a targeted manner to develop and gain market access for high quality pharmaceutical products. Fundamentally, the clinical team needs to understand product-specific, technical and business objectives of growing corporate structures. This understanding of needs and objectives helps to translate knowledge into product impact and development. The availability and flexibility to engage in clinical operational processes and growing enterprise structures is critical in this regard, especially in start-up companies where working groups are yet to find each other and work processes are yet to be defined. REAgency+ knows that when working with outsourcing providers, there are often hurdles to overcome to ensure sponsor oversight and budget planning. REAgency+’s expert solution has the corporate objective of enabling product and company identification in cooperation with and by experts.

#clinicalresearch #outsource #clinicaltrials #consulting #research #researchanddevelopment #share #like #healthcare
#biotech #pharma #medicine #oncology #lifescience
#clinicaldevelopment #clinicaltrial #ClinicalResearchOrganisation